Artivion (NYSE:AORT) Coverage Initiated by Analysts at JMP Securities

JMP Securities started coverage on shares of Artivion (NYSE:AORT) in a report issued on Wednesday, MarketBeat.com reports. The firm issued an outperform rating and a $33.00 price objective on the stock.

AORT has been the subject of several other research reports. Lake Street Capital lifted their price objective on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Oppenheimer boosted their price target on Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Stifel Nicolaus increased their price objective on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Artivion in a research note on Friday, September 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Artivion has an average rating of “Buy” and a consensus price target of $30.60.

Artivion Price Performance

AORT opened at $26.86 on Wednesday. The stock has a fifty day moving average price of $25.84 and a 200 day moving average price of $24.59. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. Artivion has a 1 year low of $12.16 and a 1 year high of $29.24. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -111.92 and a beta of 1.74.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.04. The business had revenue of $98.02 million during the quarter, compared to analyst estimates of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. Analysts forecast that Artivion will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In related news, VP Matthew A. Getz sold 9,420 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the transaction, the vice president now owns 34,116 shares of the company’s stock, valued at approximately $863,475.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Matthew A. Getz sold 9,420 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $25.31, for a total transaction of $238,420.20. Following the transaction, the vice president now owns 34,116 shares of the company’s stock, valued at approximately $863,475.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at approximately $3,664,912.02. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,109 shares of company stock worth $951,935 over the last ninety days. Company insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

Institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in Artivion in the 2nd quarter valued at approximately $28,000. GAMMA Investing LLC raised its stake in shares of Artivion by 38.6% in the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after purchasing an additional 505 shares in the last quarter. RiverPark Advisors LLC acquired a new position in shares of Artivion in the second quarter valued at $55,000. Register Financial Advisors LLC bought a new position in Artivion in the first quarter worth $114,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in Artivion by 291.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock worth $118,000 after buying an additional 4,154 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.